St Luke's precision oncology program reports improved outcomes for patients with @saintlukeskc molecular tumor board-directed therapy at the ESMO conference in Madrid
Just published in JTO: https://t.co/SfaGyq2xMw
STK11 and KEAP1 mutations confer less OS and PFS benefit in metastatic NSCLC, but ICI doublets might overcome the resistance.
Thank you @RamSubraMD @dhruvsxu for guiding this project through!
Great talk by @RamSubraMD making the case that The Future of Lung Cancer Screening in High Risk Non-Smokers is already here!
➡️ family history, biomarkers can select non- smokers at risk
#lcsm@FLASCO_ORG Early Lung Cancer Summit
@LuisERaez1